Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal VALENSI Jurnal Radioisotop dan Radiofarmaka Majalah Kedokteran Bandung
Veronika Yulianti Susilo
PTPRR-PUSPIPTEK
Chemistry Medicine & Pharmacology

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

 1 
PENGARUH WAKTU DAN SUHU INKUBASI PADA OPTIMASI ASSAY KIT RIA MIKROALBUMINARIA Susilo, Veronika Yulianti; Mondrida, Gina; Setiyowati, Sri; Sutari, .; Lestari, Wening
Jurnal Radioisotop dan Radiofarmaka Vol 8 (2005): JURNAL PRR 2005
Publisher : Jurnal Radioisotop dan Radiofarmaka

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (106.817 KB)

Abstract

Penentuan kadar albumin dalam jumlah mikro dalam urin pasien sangat penting dilakukan untuk deteksi dini mikroalbumin sebelum menjadinephropathy(gagal ginjal). Penentuan kadar mikroalbumin tersebut menggunakan teknik radioimmunoassay(RIA) dengan kit RIA Mikroalbuminuria. Kit RIA yang baru harus memberikan kinerja assayyang baik, maka setelah diproduksi komponen kit RIA Mikroalbuminuria yang memenuhi syarat perlu dilakukan rancangan assayyang tepat agar diperoleh kondisi assayyang optimum. Telah dilakukan optimasi rancangan assaykit RIA Mikroalbuminuria untuk memperoleh waktu dan suhu inkubasi yang terbaik, yaitu variasi waktu inkubasi 1 jam, 3 jam, 5 jam dan 18 jam dan suhu inkubasi 4°C, 25°C dan 37°C. Protokolassayyang optimum dicapai dengan inkubasi selama 3 jam pada 37°C, yang menghasilkan % ikatan maksimum sebesar 52% dan ikatan non spesifik (NSB) cukup rendah 0,15%. Kit RIA Mikroalbuminuria ini stabil memenuhi syarat %B/T dan %NSB dan dapat dipertahankan selama 8 minggu. Kata kunci: Optimasi, Radioimmunoassay, Mikroalbuminuria Determination of albumin content at micro quantity in a patient urine is very important for an early detection of microalbuminuria before a nephropathy (kidney failure) state to occure. Determination of albumin content in a patient urine is by radioimmunoassay technique using microalbuminuria RIA kit. In a production of a new. icroalbuminuria RIA Kit, a good assay performance should be quaranteed, therefore after RIA reagent that fulfil the required quality were obtained, an optimum assay condition should be esigned. Optimization for assay design of microalbuminuria RIA kit have been carried out in order to obtained the best incubation time and temperature. Incubation time and temperature investigated were 1 hour, 3 hour, 5 hour and 18 hour and 4°C, 25°C dan 37°C respectively. The optimum assay protocol was achieved by 3 hour incubation at 37°C, resulting a high maximum binding of 52% and very low non spesific binding (NSB) of 0,15% respectively. The microalbuminuria RIA kit was stable and comply the required %B/T and %NSB up to 8 weeks. Keywords: Optimize, Radioimmunoassay, Microalbuminuria.
Immunoradiometricassay (IRMA) CA 15.3 untuk Deteksi Kanker Payudara Widayati, Puji; Lestari, Wening; Susilo, Veronika Yulianti
Jurnal Radioisotop dan Radiofarmaka Vol 17, No 1 (2014): Jurnal PTRR 2014
Publisher : Jurnal Radioisotop dan Radiofarmaka

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1401.467 KB)

Abstract

Kanker payudara merupakan salah satu masalah kesehatan karena angka morbiditas dan mortalitas yang cukup tinggi. Tingginya angka mortalitas dikarenakan terapi yang ada sekarang ini belum memberikan hasil yang memuaskan. Tingginya tingkat stadium pasien kanker payudara di Indonesia disebabkan tingkat kesadaran masyarakat yang rendah, pada hal kanker payudara adalah salah satu jenis kanker yang dapat dideteksi dini, salah satu caranya dengan menggunakan kit IRMA CA 15.3. Carbohydrate Antigen 15.3 (CA 15.3) adalah sejenis gabungan glikoprotein heterogene yang dapat bereaksi dengan monoklonal antibodi anti CA 15.3. Senyawa CA 15.3 digunakan sebagai tumor marker dan penentuan kadarnya dapat dilakukan dengan teknik Immunoradiometricassay (IRMA). Pusat Radiosotop dan Radiofarmaka (PRR)-BATAN telah mengembangkan kit IRMA CA 15.3 dan sebelum digunakan secara klinis kit tersebut harus divalidasi. Penelitian ini bertujuan untuk melakukan validasi kit IRMA CA-125 produksi PRR yang meliputi penentuan batas deteksi, kepekaan (sensitivitas), ketelitian (presisi) dan parameter assay (Non Spesific Binding, NSB dan Maximum Binding, MB) sehingga dapat digunakan untuk menentukan kadar CA 15.3 pada pasien kanker payudara di rumah sakit. Telah dilakukan validasi kit IRMA CA 15.3 yang menghasilkan batas deteksi 0,84 mIU/mL dengan ketelitian intra assay memberikan koefisien variasi (%CV) untuk QCL (8,94%) dan QC H (7,99%) sedangkan ketelitian inter assay untuk QC L (11,94%) dan QC H(12,38%). Kit IRMA CA 15,3 ini mempunyai karakter yang baik sesuai dengan %NSB dan B/T yang ditunjukkannya (1,05 untuk %NSB dan 16,30% untuk B/T).ABSTRACTCANCER DETECTION. Breast cancer is one health problem because the rate of morbidity and mortalityare quite high. The high mortality rate due to the existing therapy to breast cancer patients did not givesatisfactory results. The high stage breast cancer patients in Indonesia due to the low level of public awareness, whereas breast cancer is one type of cancer that can be early detected, using CA 153 IRMA kit. The Carbohydrate antigen 15.3 (CA-153) is a kind of combination of heterogene glycoprotein which canreact with the monoclonal anti CA 153 antibody. The CA 153 compound can be used as tumor marker and the concentration can be detennined using IRMA technique. The Center for Radiosotope and Radiohannaceuticals (CRR)-BA TAN has developed a CA 153 IRMA kit to fullfil domestic demand. The aim of the study is to validate the CA-125 IRMA kit produced by CRR including detennination of sensitivity, accuracy, precision and the assay parameters (Non-specific binding, NSB and Maximum Binding, MB) of the kit in order to be used to detennine concentration ofCA 153 of patients in the hospital. IRMA kit validation has been carried out resulting detection limit for CA 15.3 at 0.8130 IV I mL withprecision CY for intra-assay QC L (8,94%CY) and QC H(7.99%CY) while the inter-assay precision for QC L (l1,94%CY) and QC H. (l2,38%CY). This CA 153 IRMA kit also has a good character showing 1,05% NSB and 16,30%BIT.Keywords: Radiometricassay, tumour marker, CA 1531
VALIDASI KIT RADIOIMMUNOASSAY AFLATOKSIN 81 Widayati, Puji; Ariyanto, Agus; Triningsih, Triningsih; Susilo, Veronika Yulianti; Lestari, Wening
Jurnal Radioisotop dan Radiofarmaka Vol 18, No 1 (2015): JURNAL PTRR 2015
Publisher : Jurnal Radioisotop dan Radiofarmaka

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (2239.377 KB)

Abstract

Aflatoksin merupakan senyawa mikotoksin yang bersifat sangat toksik sehingga dapat menjadi penyebab terjadinya kanker pada manusia. Aflatoksin berpotensi karsinogenik, mutagenik, teratogenik, dan bersifat imunosupresif oleh karena itu kandungan aflatoksin B1 dalam bahan dan prod uk pangan harus dibatasi. Salah satu teknik penentuan kadar aflatoksin B1 adalah radioimmunoassay (RIA) yang didasarkan pada reaksi immunologi antara antigen dan antibodi yang spesifik hanya untuk antigen tertentu saja, serta menggunakan antigen yang ditandai zat radioaktif sebagai peru nut. Pusat Teknologi Radioisotop danRadiofarmaka BATAN telah berhasil mengembangkan kit RIA Aflatoksin B1 yang dapat digunakan untuk penentuan kandungan Aflatoksin B1dalam bahan dan produk pangan. Sebelum digunakan di lapangan kit aflatoksin B1 harus divalidasi meliputi penentuan batas deteksi, kepekaan (sensitivitas), ketelitian (presisi) dan parameter assay (Non Spesific Binding, NSB dan Maximum Binding, MB) sehingga dapat digunakan untuk menentukan kadar aflatoksin B1• Penelitian ini bertujuan untuk menentukan batas deteksi, ketelitian intra assay dan inter assay serta parameter assay. Telah dilakukan validasi kit RIA aflatoksin yang menghasilkan batas deteksi 0,35 ng/mL dengan ketelitian intra assay memberikan koefisien variasi (%CV) QC 9,80% sedangkan ketelitian inter assay untuk QC 12,39%. Kit RIA aflatoksin B1 ini disimpulkan memberikan unjuk kerja yang baik karena menghasilkan %NSB sebesar 6,6 dan B/T sebesar 47,18. Aflatoxins are mycotoxins compounds that are highly toxic and carcinogenic. Aflatoxins are potentially carcinogenic, mutagenic, teratogenic, and immunosuppressive so that the content of aflatoxin B1 in food products should be limited. One technique of determining the level of aflatoxin B1 is a radioimmunoassay (RIA) which is based on immunological reactions between antigens and antibodies, and using radioactive substances as a tracer. Center for Radioisotopes and Radiopharmaceuticals Technology (PTRR) has successfully developed Aflatoxin B1 RIA kit that can be used to determine the aflatoxin B1 in food products. Aflatoxin B1 RIA kit must be validated, which includes determining the limits of detection, sensitivity, accuracy (precision) and assay parameters (Non Specific Binding, NSB and Maximum Binding, MB) that can be used to determine the level of aflatoxin B1. This study aims to determine the limit of detection, accuracy intra-assay and inter-assay and assay parameters. The Aflatoxin B1 RIA kit validation results in the detection limit of 0.35 ng / mL with coefficient of variation (% CV) QC 9.80%, while the inter-assay precision for QC 12.39%. RIA Kit Aflatoxin B1 is inferred provide good performance because it produces 6.6% for NSBand 47.18 for B/T.  
Perancangan Hewan Coba Model untuk Karsinoma Payudara HER-2 Positif Menggunakan Agen Imunosupresan Hidayat, Basuki; Massora, Stepanus; Ramli, Martalena; Susilo, Veronika Yulianti; Arianto, Agus; Masjhur, Johan S.
Majalah Kedokteran Bandung Vol 48, No 1 (2016)
Publisher : Faculty of Medicine, Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (441.256 KB)

Abstract

Pengembangan obat terapi keganasan di Indonesia sering kali terkendala karena ketidakmampuan menyediakan hewan model untuk uji preklinis. Hewan model tersebut adalah hewan model dengan massa keganasan yang mempunyai karakteristik khusus, bukan sekedar dengan massa tumor. Pada umumnya untuk tujuan tersebut digunakan hewan model yang tidak mempunyai daya tahan tubuh dan dipelihara dalam lingkungan yang steril. Fasilitas sistem perkandangan yang steril ini yang belum ada di Indonesia. Tujuan penelitian ini mengembangkan metode penyediaan hewan model mencit pengganti nude mice dengan daya tahan tubuh yang rendah, tetapi mampu hidup dalam lingkungan fasilitas pemeliharaan yang tidak steril. Penelitian dilakukan di Laboratorium Hewan dan Laboratorium Sitogenetik Pusat Teknologi Radioisotop dan Radiofarmaka, Batan, Serpong sejak bulan Juli sampai November 2014. Galur sel SKBR-3 diinokulasi pada 2 kelompok mencit sehat (Mus musculus) strain Balb/c, yaitu kelompok perlakuan dan kontrol, masing-masing 8 ekor. Cyclosporine A, agen penurun daya tahan tubuh hanya diberikan pada kelompok perlakuan sebelum dan setelah inokulasi. Pada kedua kelompok, pertumbuhan tumor secara makroskopik tidak terlihat di tempat inokulasi, tetapi tampak perbedaan bermakna antara kelompok perlakuan dan kontrol pada kadar leukosit (p:0,01), limfosit (p:0,01), monosit (p:0,01), dan segmen neutrofil (p:0,01). Pada 2 mencit kelompok perlakuan didapatkan gambaran sel degenerasi bengkak keruh di hati. Metode ini terbukti dapat menurunkan daya tahan tubuh hewan coba mencit (Mus musculus) strain Balb/c, walaupun belum mampu menumbuhkan keganasan. [MKB. 2016;48(1):39–44]Kata kunci: Ca payudara HER2 positif, hewan coba model onkologiDesigning Animal Models for HER2 Positive Breast Cancer Using Immunosuppressive AgentAbstractThe development of therapeutic drug for malignancy in Indonesia is often constrained because of the inability to provide animal models for preclinical study. These animal models are an animal model with a malignancy mass which have special characteristics, not just the tumor mass. Animal models that are usually used for this purpose is immunodeficient animals. This animal must be kept in sterile animal care, but the facility is not readily available in Indonesia. The purpose of this study was to develop a method for providing an animal model of nude mice replacement that has fairly low immunity but are still able to live in non-sterile animal care facilities. The study was conducted at the Laboratory Animal and Cytogenetics, Center for Radioisotope and Radiopharmaceuticals Technology, Batan, Serpong in the period of July to November 2014. SKBR-3 cell lines were inoculated on two groups of immunocompetent mice (Mus musculus) strain Balb/c, namely the treatment group (n=8) and controls (n=8). Cyclosporine A as an immunosupressan agent was given only to the treatment group before and after SKBR 3 inoculation. No macroscopically visible tumor growth at the site of inoculation in both of groups. There was a significant difference between the treatment group and the control group in leukocyte levels (p: 0.01), lymphocytes (p: 0.01), monocytes (p: 0.01), and neutrophil segments (p: 0.01). Two treatment groups of mice obtained cloudy degeneration in the liver. This method has significantly reduced the immunity of mice (Mus musclus) strain Balb/c but still cannot grow malignancies in experimental animals. [MKB. 2016;48(1):39–44]Key words: HER2 positive breast cancer, oncology animal models DOI: 10.15395/mkb.v48n1.732
Radiolabeling and In-Silico Study of 131I-(4-fluorobenzoyl-3-methylthiourea) as Radiopharmaceuticals for Breast Cancer Theranostics Pratama, Febby; Ruswanto, Ruswanto; Nofianti, Tita; Pratita, Anindita Tri Kusuma; Daruwati, Isti; Susilo, Veronika Yulianti; Holik, Holis Abdul
Jurnal Kimia Valensi Jurnal Kimia VALENSI, Volume 10, No. 1, May 2024
Publisher : Syarif Hidayatullah State Islamic University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15408/jkv.v10i1.34258

Abstract

The chemicals produced from thiourea are actively being studied as anticancer possibilities. In complexes with radionuclides like Iodine-131, the 1-(4-Fluorobenzoyl)-3-methyl thiourea is a promising ligand for theragnostic applications. This study aimed to label 1-(4-fluorobenzoyl-3-methylthiourea) with iodine-131 and observe its interaction with breast cancer receptors. The radiolabeling of 131I-(4-fluorobenzoyl-3-methylthiourea) uses the radioiodination method with Chloramine-T, and an in-silico investigation of breast cancer receptors was conducted. According to the results of molecular docking using AutoDockTools, this radiopharmaceutical molecule has the best activity on the HER2 receptor (PDB ID: 3PP0) compared to the native ligand and control positive, with a binding affinity of -6.13 kcal/mol and a Ki value of 32.05 mM. According to the molecular dynamics data using Desmond, the radiopharmaceutical molecule 131I-(4-Fluorobenzoyl-3-methylthiourea) displays good stability starting from the 50ns range. The indirect radioiodination method has successfully labeled 1-(4-Fluorobenzoyl-3-methylthiourea) with iodine-131.
Co-Authors . Sutari Agus Arianto, Agus Agus Ariyanto Basuki Hidayat Gina Mondrida Holis Abdul Holik, Holis Abdul Isti Daruwati Johan S. Masjhur, Johan S. Martalena Ramli Pratama, Febby Pratita, Anindita Tri Kusuma Puji Widayati Ruswanto, Ruswanto Sri Setiyowati Stepanus Massora, Stepanus Tita Nofianti, Tita Triningsih Triningsih Wening Lestari